ArticleNucleic acids research2026
Rapid discovery of monoclonal antibodies via high-throughput single BCR affinity sequencing.
Mengzhu Hu, Qiuyu Lian, Xiaonan Cui, Xiao Chen, Xue Dong, Mengge Huang, Guangchao Wang, Yan Hu, Hao Zhang, Jiacan Su and 2 more
Abstract read
In one paragraphArticle in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Mengzhu HuSingle Cell Systems Biology Laboratory, College of Marine Life Sciences, Ocean University of China, Qingdao, Shandong 266100, China.ORCID 0009-0002-9651-2889 Qiuyu LianGurdon Institute, Tennis Court Road, University of Cambridge, Cambridge CB2 1QN, United Kingdom.
Xiaonan CuiState Key Laboratory of Microbial Technology, Shandong University, Qingdao 266237, China.
Xiao ChenDepartment of Orthopedics, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
Xue DongOncology Department, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Provincial University Laboratory of Clinical Immunology and Translational Medicine, Shandong Lung Cancer Institute, Jinan 250014, China.
Guangchao WangDepartment of Orthopedics, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
Yan HuDepartment of Orthopedics, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
Hao ZhangDepartment of Orthopedics, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
Jiacan SuDepartment of Orthopedics, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.ORCID 0000-0001-7080-263X Hongyi XinGlobal Institute of Future Technology, Shanghai Jiao Tong University, Shanghai 200240, China.
Weiyang ShiDepartment of Orthopedics, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
Funding
China Postdoctoral Science Foundation 2025M772584GuangDong Basic and Applied Basic Research Foundation 2023B1515120006Lingang Laboratory Grant LGL-8888 20DZ2254400Lingang Laboratory Grant LGL-8888 24510714300Natural Science Foundation of China 32370863Natural Science Foundation of China 32500068Natural Science Foundation of China 62102250Natural Science Foundation of China 62103273Science-Medicine interdisciplinary YG2026ZD09Shandong Provincial Postdoctoral Innovation Project SDCX-ZG-202503010STI2030-Major Projects 2022ZD0212400
6 · The paper itselfAbstract
To jointly capture antigen-binding affinity and paired heavy-light-chain sequences at scale has remained a bottleneck for monoclonal antibody discovery. Here, we present Antigen Affinity BCR-seq (AAB-seq), a high-throughput single-cell sequencing platform that can obtain the relative antibody-antigen affinity of thousands of paired native BCR sequences. AAB-seq employs dual-labeled antigens and DNA-barcoded anti-light-chain antibodies to compute an AAB score that is proportional to antibody-antigen binding strength. Integrated with a rapid, low-cost direct cloning workflow, it enables affinity-guided antibody retrieval without de novo antibody gene synthesis. Validated against ovalbumin and SARS-COV-2 RBD, AAB-seq discovered potent antibodies whose AAB score correlates strongly with ELISA, including novel SARS-COV-2 neutralizing antibodies with potent effector functions. Together, AAB-seq accelerates antibody screening and potentially provides large-scale sequence-affinity datasets for machine learning-driven therapeutic antibody design and development.
Indexed as
Antibodies, MonoclonalAntibody AffinityHigh-Throughput Nucleotide SequencingAnimalsAntibodies, NeutralizingAntibodies, ViralCOVID-19HumansImmunoglobulin Light ChainsOvalbuminSARS-CoV-2Single-Cell AnalysisSpike Glycoprotein, CoronavirusAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralImmunoglobulin Light ChainsOvalbuminSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
PMID42621736
PMCPMC13490948
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390